Stocktoria
NEOGEN CORP NEOG
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1989-08-23
NEOGEN CORP financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $894.7M | $924.2M | $822.4M | $527.2M | $468.5M |
| Gross profit | $421.4M | $463.9M | $406.0M | $243.0M | $215.1M |
| R&D expense | $21.1M | $22.5M | $26.0M | $17.0M | $16.2M |
| Operating income | -$1.1B | $58.7M | $37.5M | $58.6M | $74.2M |
| Interest expense | $38.1M | $42.2M | $27.3M | — | — |
| Income tax | -$41.1M | -$4.9M | $828,000 | $11.9M | $14.4M |
| Net income | -$1.1B | -$9.4M | -$22.9M | $48.3M | $60.9M |
| EPS (diluted) | $-5.03 | $-0.04 | $-0.12 | $0.45 | $0.57 |
| Operating cash flow | $58.2M | $35.3M | $41.0M | $68.0M | $81.1M |
| Cash & equivalents | $129.0M | $170.6M | $163.2M | $44.5M | $75.6M |
| Inventory | $190.8M | $189.3M | $133.8M | $122.3M | $100.7M |
| Total assets | $3.4B | $4.5B | $4.6B | $992.9M | $920.2M |
| Total liabilities | $1.4B | $1.4B | $1.4B | $105.6M | $79.8M |
| Shareholders' equity | $2.1B | $3.1B | $3.1B | $887.4M | $840.4M |
Source: SEC EDGAR filings · CIK 0000711377 · as of 2025-05-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.